MA56001A - Formes de sel cristallin d'un inhibiteur de kinase - Google Patents
Formes de sel cristallin d'un inhibiteur de kinaseInfo
- Publication number
- MA56001A MA56001A MA056001A MA56001A MA56001A MA 56001 A MA56001 A MA 56001A MA 056001 A MA056001 A MA 056001A MA 56001 A MA56001 A MA 56001A MA 56001 A MA56001 A MA 56001A
- Authority
- MA
- Morocco
- Prior art keywords
- kinase inhibitor
- salt forms
- crystalline salt
- crystalline
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962856404P | 2019-06-03 | 2019-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA56001A true MA56001A (fr) | 2022-04-06 |
Family
ID=69160360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA056001A MA56001A (fr) | 2019-06-03 | 2019-12-12 | Formes de sel cristallin d'un inhibiteur de kinase |
Country Status (18)
Country | Link |
---|---|
US (1) | US20230052703A1 (fr) |
EP (1) | EP3976587A1 (fr) |
JP (1) | JP2022535072A (fr) |
KR (1) | KR20220016117A (fr) |
CN (1) | CN113939503B (fr) |
AU (1) | AU2019449809A1 (fr) |
BR (1) | BR112021024300A2 (fr) |
CA (1) | CA3139148A1 (fr) |
CL (1) | CL2021003205A1 (fr) |
CO (1) | CO2021017343A2 (fr) |
CR (1) | CR20210616A (fr) |
DO (1) | DOP2021000236A (fr) |
IL (1) | IL288484A (fr) |
MA (1) | MA56001A (fr) |
MX (1) | MX2021014773A (fr) |
PE (1) | PE20220962A1 (fr) |
SG (1) | SG11202111978VA (fr) |
WO (1) | WO2020247019A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020015201A2 (pt) * | 2018-01-26 | 2020-12-29 | Exelixis, Inc. | Compostos para tratamento contra distúrbios dependentes de quinase |
US20230029213A1 (en) * | 2018-12-13 | 2023-01-26 | Exelixis, Inc. | Crystalline Forms and Salt Forms of a Kinase Inhibitor |
TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
TW202340148A (zh) | 2021-12-22 | 2023-10-16 | 美商艾克塞里克斯公司 | 激酶抑制劑之結晶形式及鹽形式 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2466818T3 (es) * | 2003-09-26 | 2014-06-11 | Exelixis, Inc. | Moduladores c-Met y métodos de uso |
EP1871417B1 (fr) | 2005-04-15 | 2013-09-11 | Precision Biologics, Inc. | Anticorps monoclonaux recombinés et antigènes correspondants contre les cancers du colon et du pancréas |
CA3139031A1 (fr) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation |
US9815897B2 (en) | 2013-05-02 | 2017-11-14 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
US20180009758A1 (en) * | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
MX2019012505A (es) * | 2017-05-26 | 2019-12-19 | Exelixis Inc | Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso. |
BR112020015201A2 (pt) | 2018-01-26 | 2020-12-29 | Exelixis, Inc. | Compostos para tratamento contra distúrbios dependentes de quinase |
CN109761899B (zh) * | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2019
- 2019-12-12 CN CN201980097028.2A patent/CN113939503B/zh active Active
- 2019-12-12 JP JP2021571744A patent/JP2022535072A/ja active Pending
- 2019-12-12 PE PE2021002015A patent/PE20220962A1/es unknown
- 2019-12-12 EP EP19836340.0A patent/EP3976587A1/fr active Pending
- 2019-12-12 CA CA3139148A patent/CA3139148A1/fr active Pending
- 2019-12-12 SG SG11202111978VA patent/SG11202111978VA/en unknown
- 2019-12-12 US US17/616,124 patent/US20230052703A1/en active Pending
- 2019-12-12 WO PCT/US2019/065980 patent/WO2020247019A1/fr active Application Filing
- 2019-12-12 BR BR112021024300A patent/BR112021024300A2/pt unknown
- 2019-12-12 CR CR20210616A patent/CR20210616A/es unknown
- 2019-12-12 MX MX2021014773A patent/MX2021014773A/es unknown
- 2019-12-12 AU AU2019449809A patent/AU2019449809A1/en active Pending
- 2019-12-12 MA MA056001A patent/MA56001A/fr unknown
- 2019-12-12 KR KR1020217041796A patent/KR20220016117A/ko unknown
-
2021
- 2021-11-17 DO DO2021000236A patent/DOP2021000236A/es unknown
- 2021-11-28 IL IL288484A patent/IL288484A/en unknown
- 2021-12-02 CL CL2021003205A patent/CL2021003205A1/es unknown
- 2021-12-16 CO CONC2021/0017343A patent/CO2021017343A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CR20210616A (es) | 2022-03-22 |
US20230052703A1 (en) | 2023-02-16 |
AU2019449809A1 (en) | 2021-12-16 |
CN113939503B (zh) | 2024-05-07 |
IL288484A (en) | 2022-01-01 |
CN113939503A (zh) | 2022-01-14 |
BR112021024300A2 (pt) | 2022-01-11 |
DOP2021000236A (es) | 2022-04-18 |
CO2021017343A2 (es) | 2022-01-17 |
EP3976587A1 (fr) | 2022-04-06 |
MX2021014773A (es) | 2022-01-18 |
KR20220016117A (ko) | 2022-02-08 |
PE20220962A1 (es) | 2022-06-10 |
CA3139148A1 (fr) | 2020-12-10 |
JP2022535072A (ja) | 2022-08-04 |
CL2021003205A1 (es) | 2022-09-30 |
WO2020247019A1 (fr) | 2020-12-10 |
SG11202111978VA (en) | 2021-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA56001A (fr) | Formes de sel cristallin d'un inhibiteur de kinase | |
MA54458A (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
MA53226A (fr) | Sel et formes cristallines d'omecamtiv mecarbil | |
MA52493A (fr) | Sels d'un inhibiteur de fgfr | |
MA55614A (fr) | Formes cristallines d'inhibiteur de pyridazinone trpc | |
IL290508A (en) | Heterocyclic compounds as kinase inhibitors | |
MA55801A (fr) | Formes solides d'un inhibiteur de glyt1 | |
IL289929A (en) | Crystal forms of cd73 inhibitor | |
MA42780A (fr) | Sels d'un inhibiteur de la kinase pim | |
IL287668A (en) | Crystalline forms of btk inhibitor | |
HUE064943T2 (hu) | Szubsztituált tiazolidin vegyület alkalmazása nitrifikációs inhibitorként | |
MA54087A (fr) | Sels cristallins d'un inhibiteur de la kallicréine plasmatique | |
MA54702A (fr) | Composé pyrimidine ou sel correspondant | |
IL284226A (en) | Crystal structures of a TGFB inhibitor | |
IL289389A (en) | Heterocyclic compounds as kinase inhibitors | |
MA53671A (fr) | Formes cristallines d'un agoniste du récepteur farnésoïde x | |
IL290087A (en) | inhibitory substances | |
ZA202109183B (en) | Novel compounds for inhibition of janus kinase 1 | |
GB201914860D0 (en) | Inhibitor compounds | |
IL267393A (en) | Crystal forms of a Janus kinase inhibitor | |
SG11202102110PA (en) | Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor | |
MA54638A (fr) | Formes cristallines d'un stimulateur de sgc | |
FI3891156T3 (fi) | Mcl-1-inhibiittorin uusia kiteisiä muotoja, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia | |
MA53561A (fr) | Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k) | |
MA41599A (fr) | Formes cristallines d'un composé pyrrolopyridine |